VC
CTMX icon

Vivo Capital’s CytomX Therapeutics CTMX Stock Holding History

Vivo Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,884,615
Closed -$12.3M – 50
2025
Q4 		$12.3M Hold
2,884,615
– – 0.79% 32
2025
Q3 		$9.2M Sell
2,884,615
-2,884,615
-50% -$6.5M 0.74% 34
2025
Q2 		$13.1M Buy
+5,769,230
New +$9.3M 1.34% 13

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital's CTMX Position: Q1 2026 in Review

Vivo Capital sold out of CytomX Therapeutics (CTMX) in Q1 2026, closing a stake of 2,884,615 shares — an estimated $12.3M sold.

Vivo Capital first reported a position in CTMX in Q2 2025 and held it in 3 quarters. The position peaked at $13.1M in Q2 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Vivo Capital reported no remaining CytomX Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Vivo Capital sold 2,884,615 CytomX Therapeutics shares in Q1 2026, an estimated $12.3M.
  • Vivo Capital first reported a position in CytomX Therapeutics in Q2 2025 and held it in 3 quarters.
  • Vivo Capital's CytomX Therapeutics position peaked at $13.1M in Q2 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.